INTRODUCTION
Chronic graft-versus-host disease (cGVHD) continues to be associated with significant morbidity and is the leading cause for late mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1, 2] . Moreover, because of rising recipient age, and the use of unrelated donors as well as peripheral blood stem cells (PBSCs) as a graft source, the incidence of cGVHD has been increasing [3] . Although major progress has been achieved in understanding the pathophysiology of acute GVHD (aGVHD), cGVHD is far less defined. Current concepts include the persistence of alloreactive T cells, a Th1-Th2 shift of the cellular immune response, defective peripheral, and central tolerance mechanisms (ie, failure of control by regulatory T cells and/or impaired negative selection of T cells in the thymus), replacement of antigen presenting cells (APCs) of the host by APCs of the donor leading to indirect antigen presentation of allo-antigens, an increasing role of B cells producing auto-and allo-antibodies against the host, and unspecific mechanisms of chronic inflammation leading to fibrosis of involved organs [4] . First-line treatment of cGVHD consists mainly of prednisone with a starting dose of 1 mg/kg/day, often combined with a calcineurin inhibitor (CNI). Evidence for first-line treatment options is based on controlled trials with the exception of severe cGVHD, which continues to be associated with interior survival [1]. Until recently,
